|
Index | - | P/E | - | EPS (ttm) | - | Insider Own | 19.80% | Shs Outstand | 8.12M | Perf Week | 136.46% |
Market Cap | 19.82M | Forward P/E | - | EPS next Y | -0.55 | Insider Trans | 0.00% | Shs Float | 4.39M | Perf Month | 110.19% |
Income | - | PEG | - | EPS next Q | -0.09 | Inst Own | 55.60% | Short Float / Ratio | 1.01% / 0.08 | Perf Quarter | 10.73% |
Sales | 0.00M | P/S | 21994.56 | EPS this Y | - | Inst Trans | -6.49% | Short Interest | 0.04M | Perf Half Y | -77.12% |
Book/sh | 8.02 | P/B | 0.28 | EPS next Y | 36.80% | ROA | - | Target Price | 8.00 | Perf Year | - |
Cash/sh | 0.02 | P/C | 99.09 | EPS next 5Y | - | ROE | - | 52W Range | 0.80 - 10.25 | Perf YTD | 114.15% |
Dividend | - | P/FCF | - | EPS past 5Y | - | ROI | - | 52W High | -77.85% | Beta | - |
Dividend % | - | Quick Ratio | 0.40 | Sales past 5Y | - | Gross Margin | - | 52W Low | 184.96% | ATR | 0.34 |
Employees | 4 | Current Ratio | 0.40 | Sales Q/Q | - | Oper. Margin | - | RSI (14) | 76.52 | Volatility | 55.23% 22.82% |
Optionable | No | Debt/Eq | 0.01 | EPS Q/Q | - | Profit Margin | - | Rel Volume | 2.56 | Prev Close | 1.88 |
Shortable | Yes | LT Debt/Eq | 0.00 | Earnings | - | Payout | - | Avg Volume | 576.05K | Price | 2.27 |
Recom | 2.00 | SMA20 | 92.78% | SMA50 | 66.47% | SMA200 | -65.44% | Volume | 1,475,651 | Change | 20.74% |
![]() | ||||||||||||||||||||||
![]() | ||||||||||||||||||||||
|
||||||||||||||||||||||
![]() | ||||||||||||||||||||||
Cardio Diagnostics Holdings, Inc., a biotechnology company, develops and commercializes epigenetics-based clinical tests for cardiovascular disease. It offers Epi+Gen, a three-year symptomatic coronary heart disease (CHD) risk assessment test targeting CHD events, including heart attacks. The company was founded in 2017 and is headquartered in Chicago, Illinois. | ||||||||||||||||||||||
![]() | ||||||||||||||||||||||
![]() |
open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR |
Upgrade your FINVIZ experience
Join thousands of traders who make more informed decisions with our premium features. Real-time quotes, advanced visualizations, backtesting, and much more.
Learn more about FINVIZ*Elite